What is CVE-2014-6721?

CVE-2014-6721 is a vulnerability in Pharmaguideline, classified under Cryptographic Issues. Published 2014-09-26.

Is CVE-2014-6721 known to be exploited?

2 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.

Vulnerability in Pharmaguideline

CVE-2014-6721

The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.

Vulnerability class: POODLE (CVE-2014-3566)

EPSS: 0.007 (47.8th percentile) — read the EPSS interpretation.

Affected products

Pharmaguideline — versions 1.2.0
N/a — versions n/a

Weakness classification (CWE)

CWE-310 — Cryptographic Issues

Public proof-of-concept exploits

References

cret@cert.org (US Government Resource, x_refsource_CERT-VN, third-party-advisory)
cret@cert.org (US Government Resource, x_refsource_CERT-VN, third-party-advisory)
cret@cert.org (x_refsource_MISC)

Frequently asked questions

What is CVE-2014-6721?: CVE-2014-6721 is a vulnerability in Pharmaguideline, classified under Cryptographic Issues. Published 2014-09-26.
Is CVE-2014-6721 known to be exploited?: 2 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.